Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy.
Breast cancer
COVID-19
Hub
Oncologic care
Pandemic
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
01
09
2020
accepted:
11
11
2020
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
During the COVID-19 pandemic, Lombardy (Northern Italy) Regional Health Council created hubs for cancer care, meant to be SARS-CoV-2-free pathways for cancer patients. The workflow of breast cancer (BC) radiotherapy (RT) in one of the hubs is presented here. Candidates to adjuvant RT during the pandemic peak of March-April 2020 were compared to those treated in the same period of 2019, and patient volume, deferral rate, and type of RT were analyzed. Statistics were calculated with χ In March-April 2020 the BC patient volume increased by 28% compared to the same period in 2019 (scheduled patients: 175 vs. 137) and amid travel restrictions it was kept high (treated patients: 136 vs. 133), mainly due to an influx from across Lombardy. RT schemes basically did not change, being already centered on hypofractionation. The increase of median time (67 vs. 74.5 days in 2019 and 2020, respectively) to the commencement of RT for low-risk patients was clinically negligible yet statistically significant ( The workload for BC was high during the pandemic peak. Hubs allowed the continuation of oncologic treatments, while mitigating the strain on frontline COVID-19 hospitals.
Identifiants
pubmed: 34191930
doi: 10.1159/000513227
pii: brc-0005-0001
pmc: PMC7801963
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-7Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
M.C.L., F.C., B.A.J.-F. received honorarium fees from Accuray Inc. outside the current work. The remaining authors declare no conflicts of interest.
Références
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281
pubmed: 32241520
Eur J Cancer. 2020 Jul;133:29-32
pubmed: 32434108
Breast. 2020 Aug;52:110-115
pubmed: 32502796
Radiother Oncol. 2020 Aug;149:89-93
pubmed: 32413527
Lancet. 2020 Jun 20;395(10241):1884-1885
pubmed: 32479827
Head Neck. 2020 Jul;42(7):1482-1490
pubmed: 32557972
Clin Transl Radiat Oncol. 2020 Mar 24;22:55-68
pubmed: 32274425
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
Adv Radiat Oncol. 2020 Apr 02;5(4):575-576
pubmed: 32363244
Radiother Oncol. 2020 Sep;150:40-42
pubmed: 32544604
Radiother Oncol. 2020 Jul;148:203-210
pubmed: 32342870
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):e160-e161
pubmed: 32354669
Radiol Med. 2020 Jul;125(7):674-682
pubmed: 32078120
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Breast. 2020 Aug;52:8-16
pubmed: 32334323
ESMO Open. 2020 Apr;5(2):
pubmed: 32295769
Ann Oncol. 2017 Oct 1;28(10):2340-2366
pubmed: 28945867
Adv Radiat Oncol. 2020 Apr 01;5(4):582-588
pubmed: 32292842
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32439716
Oncologist. 2020 Jun;25(6):463-467
pubmed: 32298029